Bilcare Limited has filed its quarterly compliance certificate under Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2026. The pharmaceutical packaging company submitted the mandatory certificate to the Bombay Stock Exchange on April 16, 2026.

Regulatory Compliance Details

The certificate was issued by MUFG Intime India Private Limited (formerly Link Intime India Private Limited), which serves as Bilcare's registrar and share transfer agent. The filing confirms compliance with SEBI's dematerialisation requirements for the quarter.

Certificate Confirmation

MUFG Intime India Private Limited confirmed in its certificate dated April 6, 2026 that all securities received from depository participants for dematerialisation during the quarter were properly processed. The registrar verified that:

• Securities received for dematerialisation were confirmed or rejected to depositories within prescribed timelines
• All security certificates were mutilated and cancelled after due verification
• Depository names were substituted in the register of members as registered owners
• Securities comprised in certificates have been listed on stock exchanges where earlier issued securities are listed

Company Information

Bilcare Limited, headquartered at 301 Kamal Kunj, 8 Shivaji Housing Society, Pune 411016, operates in the pharmaceutical packaging sector. The company maintains its registrar services through MUFG Intime India Private Limited, located at Block No 202, 2nd Floor, Akshay Complex, Off Dhole Patil Road, Pune.

Regulatory Framework

Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 mandates quarterly certification from registrar and share transfer agents regarding dematerialisation processes. This ensures transparency and compliance in the conversion of physical securities to electronic form, protecting investor interests in the capital markets.

Bilcare Limited announced the completion of multiple corporate actions following its board meeting held on March 30, 2026. The pharmaceutical packaging company executed significant transactions involving preference share redemption, warrant conversion, and subsidiary liquidation as disclosed to BSE under Regulation 30.

Preference Share Redemption Worth ₹3.15 Crore

The company successfully redeemed 31.50 lakh preference shares of Caprihans India Limited on March 23, 2026. These 0.1% Non-Cumulative, Non-Participating Redeemable Preference Shares were valued at ₹10 each, aggregating to ₹3.15 crore. This redemption was part of Caprihans India Limited's exercise to redeem 2.80 crore preference shares from the total outstanding of 16.66 crore preference shares before March 31, 2026.

Warrant Conversion and Equity Share Allotment

Bilcare exercised its right to convert 12.90 lakh warrants into equity shares of Caprihans India Limited through multiple tranches. The company had initially invested in 48.00 lakh convertible warrants at ₹200 each in December 2024, with each warrant convertible into one equity share of ₹10 at ₹200 per share.

Through these conversions, Bilcare's shareholding in Caprihans India Limited increased from 55.99% to 59.56%, strengthening its position in the investee company.

Completion of UK Subsidiary Liquidation

The board reviewed and confirmed the successful completion of voluntary liquidation of Bilcare GCS Limited, a wholly owned subsidiary in the United Kingdom. The liquidation process, conducted under applicable laws of England & Wales, was completed on March 18, 2026.

The subsidiary's minimal contribution to the group's consolidated turnover reflects its non-material status. Liquidation proceeds of GBP 195,781.83 have been remitted by the liquidator and are awaiting credit to the company's account.

Regulatory Compliance and Board Meeting Details

The board meeting commenced at 16:15 PM IST and concluded at 17:10 PM IST on March 30, 2026. Company Secretary Sagar R. Baheti signed the regulatory disclosure to BSE, ensuring compliance with SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. The company has fulfilled all disclosure requirements under Regulation 30, providing comprehensive details of the corporate actions to stock exchanges with proper documentation and annexures.